Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53/ras Peptide Vaccine +/- PAL Cells and IL-2 in Advanced Cancer
NCT00019084Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 1996
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of mutant p53 peptide pulsed dendritic cell vaccine and ras peptide-pulsed dendritic cell vaccine in breast cancer, Cervical Cancer (CC), colorectal cancer (CRC) and 3 more (2 arms), sponsored by National Cancer Institute. Primary endpoint: Endogenous and vaccine-induced cellular immunity. Started Feb 1996; status: completed.
02
Drugs
mutant p53 peptide pulsed dendritic cell vaccineras peptide-pulsed dendritic cell vaccine
03
Conditions
breast cancerCervical Cancer (CC)colorectal cancer (CRC)lung cancerovarian cancer
Beyond the preview
Go deeper on NCT00019084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019084.